首页> 外文OA文献 >SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

【2h】

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

机译：SKLB1206，一种靶向EGFR活化和T790M突变体，ERBB2，ERBB4和VEGFR2的新型口服多立糖酶抑制剂，在体外和体内显示有效的抗肿瘤活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Youli Pan; Yong Xu; Shan Feng; Shidong Luo; Renlin Zheng; Jiao Yang; Lijiao Wang; Lei Zhong; Han-Yu Yang; Bing-Lin Wang; Yang Yu; Jingjing Liu; Zhixing Cao; Xiaoyan Wang; Pan Ji; Zerong Wang; Xin Chen; Shuang Zhang; Yu-Quan Wei; Sheng-Yong Yang;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo. [J] . Youli Pan, Yong Xu, Shan Feng, Molecular cancer therapeutics . 2012,第4期

机译：SKLB1206是靶向EGFR激活和T790M突变体ErbB2，ErbB4和VEGFR2的新型口服多激酶抑制剂，在体外和体内均显示出强大的抗肿瘤活性。
2. SKLB-287, A novel oral multikinase inhibitor of EGFR and VEGFR2, Exhibits potent antitumor activity in LoVo colorectal tumor model [J] . ChenX., LiuY., YangH.-W., Neoplasma: Journal of Experimental and Clinical Oncology . 2014,第5期

机译：SKLB-287是一种新型的EGFR和VEGFR2口服多激酶抑制剂，在LoVo大肠肿瘤模型中显示出强大的抗肿瘤活性
3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo [J] . Yang L.-L., Li G.-B., Ma S., Journal of Medicinal Chemistry . 2013,第4期

机译：吡唑并[3,4-d]嘧啶衍生物的构效关系研究导致发现一种新型的多激酶抑制剂，该抑制剂可有效抑制FLT3和VEGFR2并评估其对体内外急性髓性白血病的活性
4. KTN0182A, an Anti-KIT, Pyrrolobenzodiazepine (PBD)-Containing Antibody Drug Conjugate (ADC) Demonstrates Potent Antitumor Activity In Vitro and In Vivo Against a Broad Range of Tumor Types [C] . Sergio Trombetta, Christine Lubeski, Gary C. Kemp, PEGS . 2015

机译：KTN0182A，抗试剂盒，吡咯唑二氮杂己酮（PBD）抗体药物缀合物（ADC）在体外和体内抗抗肿瘤类型的抗肿瘤活性
5. BEBT-109 a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer [O] . Fushun Fan, Minhua Zhou, Xiaolan Ye, 2021

机译：BEBT-109一种泛突变体 - 选择性EGFR抑制剂具有高效抗肿瘤活性在EGFR-突变体非小细胞肺癌中
6. SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model [O] . X. CHEN, Y. LIU, H.-W. YANG, 2014

机译：SKLB-287，EGFR和VEGFR2的新型口服多立糖酶抑制剂，在Lovo结直肠肿瘤模型中表现出有效的抗肿瘤活性

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

著录项

引文网络

相似文献

相关主题

期刊订阅